Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript

Core Points - The conference call is focused on discussing new Phase I immunological data for TG4050, a product of Transgene [2] - Key personnel involved in the call include Dr. Alessandro Riva, Chairman and CEO, and Katell Bidet Huang, Head of Translational Medicine, who recently presented a poster at the SITC conference [2][3] - The discussion will cover how the new data fits within Transgene's strategy in the individualized neoantigen therapeutic vaccine field [3] Company Overview - Transgene is actively engaging in the development of individualized neoantigen therapeutic vaccines, indicating a focus on personalized medicine [3] - The company is utilizing platforms such as the SITC website to disseminate research findings and enhance visibility within the scientific community [3]